Bisphosphonates and bone agents

Quick revision

Nitrogen-containing bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) stop osteoclasts from resorbing bone by blocking an enzyme in the same pathway statins act on; denosumab blocks a different resorption signal entirely; teriparatide and abaloparatide are the odd ones out — they build new bone rather than just slowing its loss.

• Nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway inside osteoclasts, which impairs the cytoskeletal attachment osteoclasts need to resorb bone and drives them to apoptosis. (6)
• Oral bisphosphonates must be taken on an empty stomach with plain water, at least 30 minutes before the first food, beverage or other medication of the day, with the patient remaining upright and not lying down for at least 30 minutes, because of poor intrinsic absorption and a real esophageal irritation risk. (1)
• Osteonecrosis of the jaw and atypical, low-trauma femoral shaft fractures are labelled risks of bisphosphonates as a class, more often reported with the higher cumulative exposure typical of IV oncologic dosing but described for oral use in osteoporosis as well. (1) (2)
• Zoledronic acid (Reclast) is a once-yearly IV infusion contraindicated in patients with creatinine clearance below 35 mL/min, and it commonly causes an acute-phase reaction — fever, myalgia, flu-like symptoms — in the days after the first infusion. (2)
• Denosumab is not a bisphosphonate: it is a monoclonal antibody that binds RANKL, the signal osteoclasts need to form, function and survive, and blocking it suppresses resorption by an entirely separate mechanism. (3)
• Stopping denosumab causes a rebound rise in bone turnover and an increased risk of vertebral fracture, including multiple vertebral fractures, which is why its label calls for transitioning to another antiresorptive rather than simply discontinuing it. (3)
• Teriparatide and abaloparatide are parathyroid hormone-pathway analogs — teriparatide is PTH(1-34) itself, abaloparatide is a PTHrP(1-34) analog — and both are anabolic, stimulating new bone formation rather than only slowing resorption. (4) (5)
• Both PTH-pathway analogs caused a dose-dependent increase in osteosarcoma in rats at high, prolonged exposures, which is why both labels restrict lifetime use to no more than two years and advise avoiding them in patients with other osteosarcoma risk factors. (4) (5)

Overview

Bone is not a static scaffold: osteoclasts continuously resorb old bone and osteoblasts lay down new bone in a coupled remodelling cycle. Osteoporosis develops when resorption outpaces formation, and the two oldest strategies for treating it target opposite sides of that cycle — slow the resorption side down, or push the formation side up. Bisphosphonates, and denosumab alongside them, belong to the first strategy; teriparatide and abaloparatide belong to the second. This page groups all of them under "bone agents" because a clinician choosing among them is making exactly that antiresorptive-versus-anabolic decision, even though only the bisphosphonates share a single chemical mechanism. (6)

Within the bisphosphonates, nitrogen-containing members — alendronate, risedronate, ibandronate and zoledronic acid — are the ones in routine osteoporosis use today. They work by inhibiting farnesyl pyrophosphate synthase, an enzyme in the mevalonate pathway, inside osteoclasts. Losing that enzyme's product impairs the prenylation of small GTPases the osteoclast's cytoskeleton depends on to attach to bone, and the cell undergoes apoptosis instead of completing a resorption cycle. This is a genuinely different chemistry from the older non-nitrogen-containing bisphosphonates (etidronate, clodronate), which are instead metabolised into a toxic ATP analog — a pathway with a narrower safety margin against impairing bone mineralisation itself, which is part of why the nitrogen-containing members dominate current practice. (6)

Two long-term risks recur across every nitrogen-containing bisphosphonate label and are the ones most worth knowing cold: osteonecrosis of the jaw (ONJ), an area of exposed, non-healing jawbone usually precipitated by a dental extraction or local infection, and atypical femoral fracture (AFF), a low-trauma fracture of the femoral shaft that behaves differently from an osteoporotic fragility fracture and is often preceded by prodromal thigh or groin pain. Both are described in the alendronate and zoledronic acid labels as reported with bisphosphonate use generally, with higher absolute risk at the higher cumulative doses used in oncology than at osteoporosis doses. (1) (2)

Denosumab is grouped on this page as a bone agent rather than a bisphosphonate because it is not one, mechanistically or chemically — it is a fully human monoclonal antibody against RANKL, the ligand osteoclast precursors need to differentiate into mature, resorbing osteoclasts. Blocking RANKL suppresses resorption from a different point in the pathway than a bisphosphonate does, and unlike a bisphosphonate, denosumab's effect is not stored in bone once dosing stops — turnover rebounds, which the label ties to an increased risk of vertebral fracture, including multiple vertebral fractures, after discontinuation. (3)

Teriparatide and abaloparatide sit furthest from the bisphosphonates mechanistically. Both act through the PTH type 1 receptor — teriparatide is recombinant human PTH(1-34) itself, abaloparatide is a synthetic analog of PTH-related protein, PTHrP(1-34) — and, given intermittently, that signalling stimulates new bone formation on trabecular and cortical surfaces rather than simply slowing resorption. Both labels report the same rat carcinogenicity finding — a dose- and duration-dependent rise in osteosarcoma at exposures well above the human therapeutic dose — and both restrict lifetime treatment to no more than two years as a result, even though it remains unknown whether the finding translates to humans at labelled doses. (4) (5)

Classification and drug examples

Three genuinely different mechanisms are taught together here because they are prescribed as alternatives to one another for the same clinical problem. Only the first group is chemically "bisphosphonates"; the other two are contrast agents included for the comparison a clinician actually has to make.

Mechanism of action

Nitrogen-containing bisphosphonates bind avidly to hydroxyapatite at sites of active bone remodelling and are taken up by osteoclasts during resorption. Inside the osteoclast they inhibit farnesyl pyrophosphate synthase in the mevalonate pathway — the same biochemical pathway statins inhibit in the liver — which prevents prenylation of small GTPases the osteoclast's cytoskeleton needs to maintain its ruffled border and attach to bone. The osteoclast can no longer resorb bone effectively and undergoes apoptosis, which is why the bisphosphonate mechanism is antiresorptive rather than anabolic: it removes resorbing cells rather than adding bone-forming ones.

Molecular target

Farnesyl pyrophosphate synthase inside osteoclasts (bisphosphonates); RANKL, the osteoclast-differentiation ligand (denosumab); the PTH type 1 receptor on osteoblasts (teriparatide, abaloparatide)

Pharmacodynamic effect

Antiresorptive via osteoclast apoptosis (bisphosphonates) or osteoclast-formation blockade (denosumab); anabolic via new bone formation (teriparatide, abaloparatide) — none of these terms is literally cytocidal/cytostatic in the anti-infective sense, but the antiresorptive-versus-anabolic distinction plays the same organising role for this class

Effect kinetics

Bisphosphonates bind bone mineral for years and their effect persists long after the last dose because the drug is released slowly as bone remodels; denosumab's effect requires continued dosing and reverses within months of stopping; teriparatide and abaloparatide's anabolic effect also requires continued intermittent dosing and is typically followed by an antiresorptive agent to preserve the gained bone

1. The bisphosphonate binds hydroxyapatite at an active bone-remodelling site

   Because bisphosphonates have high affinity for bone mineral, they concentrate specifically where osteoclasts are actively resorbing rather than distributing evenly through bone. (6)

2. An osteoclast internalises the drug while resorbing that bone surface

   The osteoclast takes up the bisphosphonate as part of its normal resorptive activity, delivering the drug inside the very cell it will inactivate. (6)

3. Nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase

   This blocks the mevalonate pathway step needed to prenylate small GTPases (Rho, Rac, Rab) that the osteoclast's cytoskeleton and ruffled border depend on. (6)

4. Loss of prenylation disables the osteoclast's ability to resorb bone and triggers apoptosis

   The osteoclast detaches from the bone surface and dies rather than completing a resorption cycle, reducing the number of active resorbing cells. (6)

5. In parallel, denosumab and the PTH-pathway analogs act on different cells entirely

   Denosumab binds circulating and bone-surface RANKL before it can engage its receptor RANK on osteoclast precursors, preventing those precursors from ever maturing into resorbing osteoclasts. Teriparatide and abaloparatide instead activate the PTH1 receptor on osteoblasts, and intermittent (rather than continuous) receptor activation favours bone formation over resorption, the opposite direction from the other two mechanisms on this page. (3) (4)

Major clinical uses

Pharmacokinetics

• This page gives no dose regimens by design. Which bisphosphonate, which route, and for how long is a decision for the treating clinician working from a current prescribing reference and the patient's renal function, GI tolerance and fracture-risk category.
• The oral bisphosphonates' single most clinically important pharmacokinetic fact is not a number but an instruction: bioavailability is so low, and so sensitive to co-ingested food or liquid, that the fasting-state dosing rule is not a minor convenience — skipping it can mean the dose is not meaningfully absorbed at all. (1)
• Bisphosphonates bound to bone are released gradually over years as bone remodels, which is why their antifracture effect persists well after the last dose and why "drug holidays" are a real, guideline-discussed option for low-risk patients after several years of therapy — unlike denosumab, whose effect reverses within months of stopping. (2) (3)

Adverse effects

Common

• Esophageal irritation: Esophagitis, esophageal ulcers and esophageal erosions are described with oral bisphosphonates, which is the rationale behind the strict upright, empty-stomach dosing instructions. (1)
• Acute-phase reaction after IV infusion: Fever, myalgia, flu-like symptoms and headache occur in a meaningful proportion of patients in the days after a first zoledronic acid infusion, typically less pronounced with subsequent infusions. (2)
• Hypocalcemia: Denosumab can cause hypocalcemia, which the label states must be corrected before starting treatment, with the risk markedly higher in advanced chronic kidney disease. (3)
• Injection-site reactions and hypercalcemia: Teriparatide and abaloparatide, as daily subcutaneous injections that transiently raise PTH-pathway signalling, are associated with injection-site symptoms and transient increases in serum calcium. (4)

Serious adverse effects

• Osteonecrosis of the jaw (ONJ): Described across the bisphosphonate class and for denosumab, generally associated with a dental extraction or local infection and delayed healing; it can also occur spontaneously. A dental assessment before starting long-term bisphosphonate or denosumab therapy, and avoiding invasive dental work during treatment where possible, is standard practice; new jaw pain, swelling or exposed bone during treatment is evaluated promptly. (1) (2) (3)
• Atypical femoral fracture (AFF): A low-energy, low-trauma fracture of the femoral shaft, often preceded by weeks to months of prodromal thigh or groin pain, reported across the bisphosphonate class and with denosumab. New thigh or groin pain during long-term antiresorptive therapy is a reason to evaluate for an incomplete femoral fracture rather than assume routine musculoskeletal pain. (1) (2) (3)
• Severe hypocalcemia: Denosumab can cause severe, symptomatic hypocalcemia, including fatal cases, with substantially higher risk in patients with advanced chronic kidney disease or chronic kidney disease-mineral bone disorder. Pre-existing hypocalcemia is corrected before the first dose, and calcium is monitored, particularly in renal impairment. (3)
• Rebound vertebral fracture after denosumab discontinuation: Stopping denosumab is followed by a rebound increase in bone turnover and an increased risk of vertebral fracture, including multiple vertebral fractures occurring close together. The label directs transitioning to an alternative antiresorptive agent rather than simply stopping denosumab without a follow-on plan. (3)
• Osteosarcoma (animal finding): Both teriparatide and abaloparatide caused a dose- and duration-dependent increase in osteosarcoma incidence in rats at exposures well above the human clinical dose; it is not known whether this translates to humans at labelled doses. Both drugs are avoided in patients with other osteosarcoma risk factors (Paget's disease, unexplained elevated alkaline phosphatase, open epiphyses, prior skeletal radiation, bone metastases or a history of skeletal malignancy), and lifetime use is capped at two years. (4) (5)
• Renal impairment (bisphosphonates): Zoledronic acid is contraindicated below a creatinine clearance of 35 mL/min, and acute renal failure has been reported, particularly with rapid infusion or in patients with pre-existing renal disease or dehydration. Renal function is checked before each IV dose and hydration status assessed beforehand. (2)

Drug-specific effects

• Alendronate: The clearest labelled illustration of the fasting-dose rule: taking it with food, another beverage, or lying down afterward meaningfully reduces both absorption and safety margin against esophageal irritation. (1)
• Zoledronic acid: Uniquely among the drugs on this page requires a specific pre-infusion renal and hydration check each time it is given, because it is dosed as a bolus IV exposure rather than daily oral titration. (2)
• Denosumab: The only drug on this page whose stopping, not its starting, carries a distinct labelled fracture-risk warning. (3)
• Teriparatide, abaloparatide: The only drugs on this page with a labelled lifetime duration cap tied to a carcinogenicity signal rather than to a renal or infusion-related risk. (4) (5)

Contraindications, precautions and interactions

Contraindications

• Zoledronic acid: creatinine clearance below 35 mL/min, or evidence of acute renal impairment. (2)
• Known hypersensitivity to the specific drug is an absolute contraindication across all four agents. (1) (2) (3) (4)

Precautions

• Uncorrected hypocalcemia must be treated before starting denosumab. (3)
• Significant esophageal abnormalities that delay esophageal emptying (stricture, achalasia) are a caution for oral bisphosphonates because of the esophagitis risk. (1)
• Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior external-beam or implant radiation involving the skeleton, bone metastases, or a hereditary disorder predisposing to osteosarcoma are reasons to avoid teriparatide and abaloparatide given their osteosarcoma signal. (4) (5)
• An upcoming invasive dental procedure is a reason to discuss timing carefully with both the dentist and the prescriber before starting or continuing a bisphosphonate or denosumab, given the ONJ association. (1) (3)

Drug interactions

• Calcium, iron, magnesium or aluminium-containing products, and other oral medications taken close to the bisphosphonate dose: Meaningfully reduce oral bisphosphonate absorption, which is why the fasting window before other intake is part of the dosing instruction rather than a general suggestion. (1)
• Aspirin and NSAIDs: May add to the gastrointestinal irritation risk of oral bisphosphonates. (1)
• Other bone-active agents: Combining an antiresorptive with an anabolic agent, or switching between them, is a sequencing decision made by the treating clinician rather than a routine co-prescription. (7)

Comparison tables

High-yield exam pearls

• "Nitrogen-containing" bisphosphonates block farnesyl pyrophosphate synthase; non-nitrogen-containing ones are metabolised into a toxic ATP analog instead. (6) It is the mechanistic line examiners draw between the modern agents (alendronate, risedronate, zoledronic acid) and the older, now rarely used ones (etidronate, clodronate).
• The oral bisphosphonate dosing rule — empty stomach, plain water, upright for 30 minutes — is not a compliance nicety; bioavailability is under 1% and drops further with any co-ingested food or drink. (1) It explains why a patient who takes alendronate with breakfast may be getting essentially no drug effect at all, independent of any side effect.
• ONJ and atypical femoral fracture are both bisphosphonate-class risks, but they are opposite ends of the same drug's action: prolonged suppression of bone turnover can both starve the jaw of the remodelling it needs to heal after dental trauma and let microdamage accumulate unrepaired in the femoral shaft. (1) (2) Understanding the shared mechanistic root — over-suppressed remodelling — explains why both risks rise with cumulative bisphosphonate exposure rather than being unrelated side effects.
• Denosumab is the one bone agent on this page where stopping the drug, not starting it, has its own labelled warning. (3) Because denosumab is not stored in bone the way a bisphosphonate is, its antiresorptive effect reverses on a timescale of months, producing a rebound fracture risk that has no bisphosphonate equivalent.
• Teriparatide and abaloparatide are the only anabolic agents here, and the only two with a rat osteosarcoma signal and a two-year lifetime cap. (4) (5) It is the single fact that most reliably distinguishes this subclass from every antiresorptive agent on the page in an exam question.

Common exam traps

• Trap: Calling denosumab a bisphosphonate because it is used for the same indication. Actually: Denosumab is a RANKL-targeting monoclonal antibody with a distinct mechanism, dosing route and discontinuation risk profile from any bisphosphonate. (3)
• Trap: Assuming any antiresorptive agent can simply be stopped once bone density improves, the way a course of antibiotics ends. Actually: Bisphosphonates leave residual bone-bound drug that keeps working for years, but denosumab does not — stopping it without a follow-on antiresorptive is specifically associated with rebound vertebral fracture. (3)
• Trap: Treating teriparatide and abaloparatide as interchangeable with bisphosphonates in mechanism because both are used for osteoporosis. Actually: They are anabolic PTH-pathway agonists that build new bone, mechanistically opposite to the antiresorptive bisphosphonates and denosumab, and they carry a distinct carcinogenicity-based lifetime dosing limit that the antiresorptive agents do not share. (4)
• Trap: Assuming the oral bisphosphonate dosing instructions are about tolerability alone. Actually: They exist primarily because oral bioavailability is extremely low and highly sensitive to co-ingested food, beverage or medication — skipping the instructions can mean inadequate drug exposure, not just a higher side-effect risk. (1)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

1. What is the molecular target of nitrogen-containing bisphosphonates inside the osteoclast?

   • RANKL
   • Farnesyl pyrophosphate synthase in the mevalonate pathway
   • The PTH type 1 receptor
   • Carbonic anhydrase
   Show answer

   Answer: Farnesyl pyrophosphate synthase in the mevalonate pathway

   Nitrogen-containing bisphosphonates such as alendronate and zoledronic acid inhibit farnesyl pyrophosphate synthase, impairing the prenylation osteoclasts need for their cytoskeleton and driving them to apoptosis. (6)

2. Why must oral bisphosphonates be taken on an empty stomach with plain water and followed by remaining upright?

   • To increase the drug's half-life
   • Because oral bioavailability is extremely low and reduced further by food, other beverages or medication, and because of esophageal irritation risk
   • Because the drug is destroyed by stomach acid otherwise
   • To prevent hypocalcemia
   Show answer

   Answer: Because oral bioavailability is extremely low and reduced further by food, other beverages or medication, and because of esophageal irritation risk

   Oral bisphosphonate bioavailability is under 1% even under ideal fasting conditions and is reduced further by co-ingested food, drink or medication; remaining upright reduces esophageal reflux of the drug and the associated irritation risk. (1)

3. Which of the following is a labelled risk specifically of stopping denosumab, rather than of continuing it?

   • Osteonecrosis of the jaw
   • Rebound increase in bone turnover with increased vertebral fracture risk
   • Acute-phase reaction
   • Hypercalcemia
   Show answer

   Answer: Rebound increase in bone turnover with increased vertebral fracture risk

   Because denosumab's effect is not stored in bone the way a bisphosphonate's is, stopping it causes bone turnover to rebound, with an increased risk of vertebral fracture, including multiple vertebral fractures — the label calls for transitioning to another antiresorptive rather than simple discontinuation. (3)

4. What mechanistically distinguishes teriparatide and abaloparatide from the bisphosphonates and denosumab?

   • They are given orally
   • They are antiresorptive like the others but longer-acting
   • They act as agonists at the PTH type 1 receptor and are anabolic, stimulating new bone formation rather than only slowing resorption
   • They have no labelled long-term risks
   Show answer

   Answer: They act as agonists at the PTH type 1 receptor and are anabolic, stimulating new bone formation rather than only slowing resorption

   Teriparatide (PTH(1-34)) and abaloparatide (a PTHrP(1-34) analog) activate the PTH1 receptor on osteoblasts; given intermittently this favours new bone formation, the opposite direction from the antiresorptive bisphosphonates and denosumab. (4) (5)

5. Zoledronic acid is contraindicated at what level of renal function?

   • Creatinine clearance below 60 mL/min
   • Creatinine clearance below 35 mL/min, or acute renal impairment
   • Any degree of chronic kidney disease
   • There is no renal contraindication
   Show answer

   Answer: Creatinine clearance below 35 mL/min, or acute renal impairment

   Reclast (zoledronic acid) is contraindicated in patients with creatinine clearance below 35 mL/min or evidence of acute renal impairment, reflecting its renal elimination pathway and reports of acute renal failure with the drug. (2)

6. What finding in animal studies led both teriparatide and abaloparatide to carry a two-year lifetime-use limitation?

   • Hepatotoxicity in dogs
   • Dose-dependent increases in osteosarcoma in rats
   • Renal failure in primates
   • QT prolongation in guinea pigs
   Show answer

   Answer: Dose-dependent increases in osteosarcoma in rats

   Both drugs caused a dose- and duration-dependent increase in osteosarcoma incidence in rats at exposures well above the human clinical dose, and it is unknown whether this translates to humans, which is why both labels cap lifetime use at two years. (4) (5)

Frequently asked questions

References

1. ALENDRONATE SODIUM tablet — prescribing information DailyMed, U.S. National Library of Medicine
2. RECLAST (zoledronic acid) injection — prescribing information DailyMed, U.S. National Library of Medicine
3. PROLIA (denosumab) injection — prescribing information DailyMed, U.S. National Library of Medicine
4. FORTEO (teriparatide) injection — prescribing information DailyMed, U.S. National Library of Medicine
5. TYMLOS (abaloparatide) injection — prescribing information DailyMed, U.S. National Library of Medicine
6. Bisphosphonate StatPearls Publishing / NCBI Bookshelf, 2023
7. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis PubMed, U.S. National Library of Medicine (Arthritis & Rheumatology abstract), 2023

Related drug classes

• Systemic corticosteroids

Back to the Endocrine and metabolic drugs classification · Pharmacology Study Corner